• About us
  • Products
    • Mammowave
    • Brainwave
  • Projects
    • MammoWave – H2020
    • Rover H2020
    • MammoScreen – HORIZON
    • RadioSpin – H2020
  • News
  • Resources
    • Publications
    • Media
    • Awards
  • Contact us
  • Contact us
          • English
          • Italian
  • English
    • Italiano (Italian)

MammoScreen – Horizon-Mission-Cancer

Duration: 48 months; Starting Date: December 2022

The project MammoScreen, which we submitted in the context of the call HORIZON-MISS-2021-CANCER-02-01 “Develop new methods and technologies for cancer screening and early detection” has been selected for funding, with the total score of 15/15.

One of the goals of HORIZON-MISS-2021-CANCER-02-01 scheme is to develop and validate new methods and technologies for cancer screening and early detection, preferably non-invasive and more-inclusive than current approaches.

The overall aim of MammoScreen is to generate evidence regarding the use of MammoWave (our recently developed microwave imaging device) as breast cancer (BC) screening technique in population-based programs promoted by national or regional health systems. The clinical trial (multicentric, prospective) will involve thousands of women in at least 10 recruitment centres located in many European countries.

Expected impacts are many, including:

  • women will benefit from safe, more inclusive (no age-limitation), more comfortable (no breast compression), accessible and accurate BC screening
  • health policy makers will have the evidence to review (and expand) current population-based BC screening programs

UBT Srl has participated in this highly competitive call within a Consortium constituted by:

Toscana Life Sciences Foundation (Italy)

London South Bank University (UK)

ELAROS 24/7 Limited (UK)

Servicio De Salud De Castilla La Mancha (Spain)

Scuola IMT Alti Studi Lucca (Italy)

EVITA – Cancro Hereditário (Portugal)

Informations
Project:

Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate, inclusive and female-friendly (MammoScreen)

Grant agreement:

https://cordis.europa.eu/project/id/101097079

Call:
HORIZON-MISS-2021-CANCER-02-01 – Develop new methods and technologies for cancer screening and early detection
Acknowledgment:
This project has received funding from the European Union's Horizon Europe Framework Programme under grant agreement No 10109707079.

INTERESTED IN OUR DEVICE FOR YOUR HOSPITAL OR YOUR CLINIC?

Do not hesitate to contact us. We will be happy to inform you about our innovative medical devices

Contact us

Useful Links

  • Home
  • News
  • Contact us
  • Privacy policy
  • Cookie Policy
  • Home
  • News
  • Contact us
  • Privacy policy
  • Cookie Policy
  • Home
  • News
  • Contact us
  • Privacy policy
  • Cookie Policy
  • Home
  • News
  • Contact us
  • Privacy policy
  • Cookie Policy
45055_st_francis_md

UBT Srl

Santa Maria della Spina Str., 25
06081 Rivotorto di Assisi (PG) Italy

VAT: 03434740548

Tel: +39 3490564302
gianluigi@ubt-tech.com (Scientific)
g.raspa@ubt-tech.com (Hardware)
s.tiberi@ubt-tech.com (Business)
amministrazione@ubt-tech.com (Administration)

london2

UBT UK Division

3rd Floor 207 Regent Street, London, W1B 3HH (Registered)
103 Borough Rd, London, SE1 0AA (Operational)

Company number 13096679

Tweets by UBTsrl
Linkedin Twitter Youtube

According to the Italian Ministry of Health guidelines of 28/03/2013, the information contained in this website is exclusively intended for professional operators.

© 2023UBT S.r.l. All Rights Reserved.